{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"No response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Objective disease status is evaluated according to the 2007 revised Cheson et al. criteria. Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow (BM) must be negative if positive at baseline. Normalization of markers. Partial Response(PR) is a 50% decrease in the SPD for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes.","groups":[{"description":"Patients receive MLN8237 (alisertib) PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity","id":"OG000","title":"MLN8237"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started treatment were included in assessing response estimates.","reportingStatus":"POSTED","timeFrame":"Up to 1 year after registration","title":"Objective Response Rate (Complete Responses (CR) + Partial Responses (PR))","type":"PRIMARY","unitOfMeasure":"participants"}